XIBROM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xibrom, and when can generic versions of Xibrom launch?
Xibrom is a drug marketed by Bausch And Lomb Inc and is included in one NDA.
The generic ingredient in XIBROM is bromfenac sodium. Thirteen suppliers are listed for this compound. Additional details are available on the bromfenac sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xibrom
A generic version of XIBROM was approved as bromfenac sodium by SENTISS on January 22nd, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XIBROM?
- What are the global sales for XIBROM?
- What is Average Wholesale Price for XIBROM?
Summary for XIBROM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 88 |
Clinical Trials: | 9 |
Patent Applications: | 4,113 |
DailyMed Link: | XIBROM at DailyMed |
Recent Clinical Trials for XIBROM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sun Pharma Global FZE | Phase 1/Phase 2 |
InSite Vision | Phase 1/Phase 2 |
Frank A. Bucci, Jr., M.D. | Phase 4 |
US Patents and Regulatory Information for XIBROM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | XIBROM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 021664-001 | Mar 24, 2005 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XIBROM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch And Lomb Inc | XIBROM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 021664-001 | Mar 24, 2005 | 4,910,225 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XIBROM
See the table below for patents covering XIBROM around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 960005707 | ⤷ Subscribe | |
Japan | H02124817 | TREATMENT MEDICINE OF INFLAMMATORY AILMENT FOR LOCAL DOSAGE | ⤷ Subscribe |
Australia | 609932 | ⤷ Subscribe | |
Spain | 2052784 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XIBROM
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1586316 | SPC/GB11/054 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523 |
1586316 | 122011100019 | Germany | ⤷ Subscribe | PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
1586316 | C 2011 004 | Romania | ⤷ Subscribe | PRODUCT NAME: BROMFENAC, SARURILE SI HIDRATII SAI ACCEPTABILI FARMACEUTICACID 2-[2-AMINO-3-(4-BROMOBENZOIL)FENILACETIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/692/001; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/692/001; DATE OF FIRST AUTHORISATION IN EEA: 20110518 |
1586316 | 11C0031 | France | ⤷ Subscribe | PRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
XIBROM Market Analysis and Financial Projection Experimental
More… ↓